Colleges in Himachal Pradesh

The BPharma curriculum at ICFAI University covers Pharmaceutics, Pharmaceutical Chemistry, Pharmaceutical Analysis, Pharmacology, and Pharmacognosy. Candidates can refer to the following final semester syllabus:

• Biostatistics and Research Methodology
• Social and Preventive Pharmacy
• Pharma Marketing Management
• Pharmaceutical Regulatory Science
• Pharmacovigilance
• Quality Control and Standardization of Herbals
• Computer Aided Drug Design
• Cell and Molecular Biology
• Cosmetic Science
• Experimental Pharmacology
• Advanced Instrumentation Techniques
• Dietary Supplements and Nutraceuticals
• Project Work

Eligible students can apply by filling out the online application form available on the official website of the university. The application window for all courses generally closes approximately a week before the scheduled selection process. candidates can follow the steps given below:

Step 1: Visit the university's official website to apply.

Step 2: Click on the 'Apply Now' option.

Step 3: Download the application form and fill out the basic details to complete the application form.

Step 4: Attach the required documents and scanned colour photographs.

Step 5: Pay the application fee and submit the form.

Admission for the BPharma programme at ICFAI University, Himachal, is ongoing. The university offers a Bachelor of Pharmacy programme that follows a semester pattern. Candidates can apply for the BPharma course through the offical website before the deadline. However, the last date to complete the application form is July 29, 2024.

Yes, candidates can get admission to the Bachelor of Pharmacy at ICFAI University, Himachal Pradesh, with a minimum of 75% aggregate in Class 12. The university's eligibility criteria for admission to the BPharma programme specify a minimum aggregate of 50% and above marks in Class 12 from a recognised board, with specific subjects as outlined in the eligibility requirements. Meeting the specified eligibility criteria is essential for admission to the BPharma programme.